BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is expected to report second quarter earnings results, before market open, on Friday 14th August 2020.
Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.75 per share.
Looking ahead, the full year loss are expected at $ 3.05 per share.
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Stock Performance
According to the previous trading day, closing price of BTAI was $ 44.71, representing a 1,089.10 % increase from the 52 week low of $ 3.76 and a 37.47 % decrease over the 52 week high of $ 71.50.
The company has a market capital of $ 1.08 billion and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”BTAI” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies.
